Core D: Pharmacokinetics/Pharmacodynamics Core

核心 D：药代动力学/药效学核心

• 批准号: 10001597
• 负责人: Charles Richard Esther
• 金额: $ 23.87万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-07 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10001597
• 关键词: Airway Disease; Animal Model; Asthma; Biological; Biological Markers; Biology; Bronchoalveolar Lavage; Cell Count; Childhood; Cleaved cell; Communities; Cultured Cells; Cystic Fibrosis; Development; Doctor of Philosophy; Drug Design; Drug Kinetics; Environmental Medicine; Exhalation; Feedback; Goals; Head; Human; Immunobiology; In Vitro; Kinetics; Laboratories; Lead; Lung; Lung diseases; Mass Spectrum Analysis; Measurement; Measures; Methods; Mucins; Mucolytics; Mucous body substance; Outcome Measure; Oxidative Stress; Oxides; Pathway interactions; Pharmaceutical Preparations; Pharmacodynamics; Physiological; Principal Investigator; Pulmonology; Research Personnel; Resources; Role; Sampling; Sialic Acids; Sputum; Surface; Urea; base; biobank; clinically relevant; cytokine; experience; experimental study; human subject; in vivo Model; metabolomics; mid-career faculty; novel; pharmacodynamic biomarker; professor; repository

Abstract The Pharmacokinetics/Pharmacodynamics Core (Core D) will provide analytic resources to each of the Projects in this application to measure concentrations of drugs and relevant biomarkers within various sample types. This will primarily be accomplished using a mass spectrometric approach, with which the principal investigator has significant expertise. Methods to detect drug and drug metabolites have already been developed for both the lead (P2176) and backup (P2114) compounds and successfully utilized to assess the pharmacokinetics of these drugs when applied to the airways. Similarly, methods to measure relevant biomarkers have been developed and yield biologically plausible results in preliminary experiments. Furthermore, the Core has the capability of adding new biomarkers as the need arises.

抽象的 药代动力学/药效学核心（核心 D）将提供分析资源 本申请中的每个项目均用于测量药物和相关浓度 各种样品类型中的生物标志物。这主要是使用质量来完成的 光谱测定方法，主要研究者具有丰富的专业知识。方法 已开发出用于检测药物和药物代谢物的先导化合物 (P2176) 和 备份（P2114）化合物并成功用于评估这些化合物的药代动力学 将药物施用于气道时。同样，测量相关生物标志物的方法也已 已开发并在初步实验中产生了生物学上合理的结果。 此外，核心能够根据需要添加新的生物标志物。